Wir nutzen Cookies auf unserer Website, um sicherzustellen, dass unsere Website richtig funktioniert. Sie helfen dabei, die beste Anwendererfahrung bereitzustellen.
Indem Sie mit der Nutzung unserer Seite fortfahren, stimmen Sie dem Gebrauch von Cookies zu. Um mehr über Cookies zu erfahren, klicken Sie hier.

You appear to be from the USA. Would like to proceed to Products available in the USA?

BIDVA’s new report highlights the importance of IVDs in overcoming AMR

The British In Vitro Diagnostics Association (BIVDA) has launched its new report examining the value of IVDs. It is estimated that 70 % of clinical decisions are made using IVDs.

Report covers challenges which IVD sector is facing but also emphasizes the unique position of in-vitro-diagnostics in offering improved patient outcomes. The future of healthcare is personalized medicine, which ensures the right person gets the right treatment at the right time.

Report is focusing three key themes:

  1. Improvement: Empowering patients for better outcomes, diagnosis and treatment
  2. Impact: Increasing efficiencies and savings within the NHS
  3. Investment: Contribution to the UK economy.

These three key areas are supported by case studies, which cover wide range of topics including case study “Protecting patients from AMR consequences”. This study stresses that point-of-care testing can play a vital role in aiding the decision whether to prescribe antibiotics of not. Studies have found that C-reactive protein (CRP) point-of-care testing can reduce antibiotic prescribing by 41%, which could result in an estimated saving of £56 million per year in the UK.

BIDVA report:

Case studies: